1:38 PM Abstract No. 207 - Tracheobronchial stenting for malignant airway disease

Abstract

Purpose To investigate both the immediate and long term outcomes following self-expandable metallic stents (SEMSs) deployment for the management of tracheobronchial malignant disease. Materials and Methods We retrospectively searched our department’s database for patients treated with covered or uncovered SEMSs for the management of tracheobronchial pathology owing to local or metastatic disease. Between January 2009 and December 2010, in total 49 patients (27 male, mean age 60.9±15 years) underwent 77 SEMS insertions (57 uncovered, 20 covered). All procedures were performed in the operation room under both bronchoscopic and fluoroscopic guidance. The study’s primary endpoints included technical success, and symptomatology recurrence rates, while secondary endpoints included patients’ survival and complications rates. Baseline demographics and procedural details were recorded. Results Technical success rate was 97.9% (48/49 cases). Overall 14 kissing, 23 main bronchus, 1 distal bronchus, 9 tracheal and 2 tracheal plus main bronchus stenting deployments, were performed. The mean time follow-up was 5.5±5.9 months (range 0.03-24 months), while the symptomatology recurrence rate was 14.5% (7/48 patients) and was attributed to stent occlusion due to tumor in-growth (4/48, 8.3%), stent migration (2/48, 4.1%) and bronchospasm (1/48, 2%). According to the Kaplan-Meyer analysis the estimated patients’ survival rate was 21.5%, up to 2-years follow-up, while the overall complications rate was 3.8% (3/77 stents). Conclusion Tracheobronchial SEMS stenting is a safe and effective minimally invasive management option for patients suffering from symptomatic malignant airway disease.